Labs Limited ("the Company") has
As filed · General Updates
M&AWatchMajormateriality 77 out of 100
What happened
FactLabs Limited ("the Company") has.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
RevisedEarlierQ4 FY25
Normally our maintenance CAPEX is about Rs. 60 – Rs. 70 crore a year.
NowQ1 FY27
Secondly would be around some of the high-end radiology centers that we are slowly rolling out, whether it is in Delhi NCR and other Tier 2 markets in North, that is also a bit of capex that we put in besides our maintenance annual capex that we do.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -96.67%.confidence 60%
Watch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- next year I think we should be better than that, maybe between 11% - 12%. (management committed by FY26)
- we believe that we should be able to recover quickly in the next 1-2 quarters. (management committed by H1 FY26)
Evidence
- Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates - Update on Acquisition(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%